These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1025 related items for PubMed ID: 12719279

  • 1. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
    Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP, Ezetimibe Study Group.
    Circulation; 2003 May 20; 107(19):2409-15. PubMed ID: 12719279
    [Abstract] [Full Text] [Related]

  • 2. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Ezetimibe Study Group.
    Am Heart J; 2004 Sep 20; 148(3):447-55. PubMed ID: 15389231
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.
    Leiter LA, Bays H, Conard S, Bird S, Rubino J, Hanson ME, Tomassini JE, Tershakovec AM.
    Am J Cardiol; 2008 Dec 01; 102(11):1495-501. PubMed ID: 19026303
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
    Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS, Tomassini JE, Tershakovec AM.
    Am J Cardiol; 2008 Dec 01; 102(11):1489-94. PubMed ID: 19026302
    [Abstract] [Full Text] [Related]

  • 5. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, Sapre A, Donahue SR, Ezetimibe Study Group.
    Clin Ther; 2004 Nov 01; 26(11):1758-73. PubMed ID: 15639688
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
    Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J.
    Am Heart J; 2005 Mar 01; 149(3):464-73. PubMed ID: 15864235
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, Tribble D, Veltri E, Mitchel Y.
    Clin Ther; 2006 Jun 01; 28(6):849-59. PubMed ID: 16860168
    [Abstract] [Full Text] [Related]

  • 9. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S, Sager P, Lipka L, Melani L, Suresh R, Veltri E, Ezetimibe Study Group.
    J Womens Health (Larchmt); 2004 Dec 01; 13(10):1101-7. PubMed ID: 15650343
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).
    Zieve F, Wenger NK, Ben-Yehuda O, Constance C, Bird S, Lee R, Hanson ME, Jones-Burton C, Tershakovec AM.
    Am J Cardiol; 2010 Mar 01; 105(5):656-63. PubMed ID: 20185012
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, Kim HS, Park SH, Seo HS, Shin DG, Shin YW, Shim WJ, Ahn TH, Ho Yun K, Yoon MH, Cha KS, Choi SW, Han SW, Hyon MS.
    Clin Ther; 2007 Nov 01; 29(11):2365-73. PubMed ID: 18158077
    [Abstract] [Full Text] [Related]

  • 12. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG, Ballantyne CM, Hsueh W, Rosen J, Lin J, Shah A, Lowe RS, Hanson ME, Tershakovec AM.
    J Clin Lipidol; 2011 Nov 01; 5(6):474-82. PubMed ID: 22108151
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.
    Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J.
    Am J Cardiol; 2004 Jun 15; 93(12):1487-94. PubMed ID: 15194018
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW, Sisk CM, Mitchel Y, Pasternak RC.
    Am Heart J; 2009 Feb 15; 157(2):352-360.e2. PubMed ID: 19185645
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M, LCP-AtorFen Investigators.
    Clin Ther; 2009 Dec 15; 31(12):2824-38. PubMed ID: 20110022
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease.
    Cruz-Fernández JM, Bedarida GV, Adgey J, Allen C, Johnson-Levonas AO, Massaad R.
    Int J Clin Pract; 2005 Jun 15; 59(6):619-27. PubMed ID: 15924587
    [Abstract] [Full Text] [Related]

  • 20. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P, IN-PRACTICE study.
    Int J Clin Pract; 2010 Jul 15; 64(8):1052-61. PubMed ID: 20487050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.